The shadow of generic challenges has consistently loomed around copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the outlook of related drug ventures. While first years saw substantial gains, the patent expiration has opened the door for less expensive copies, possibly reducing revenue and posing a genuine risk for stakeholders